Suppr超能文献

老年患者的转移性黑色素瘤:免疫见解和治疗结果。

Metastatic melanoma in the older patient: immunologic insights and treatment outcomes.

机构信息

University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):185-93. doi: 10.1586/erp.11.14.

Abstract

Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that is almost uniformly fatal for the majority of patients with the currently available treatment modalities. Since melanoma is an immunogenic tumor, developing novel immune strategies will continue to play a critical role in designing effective treatment modalities for those at high risk of recurrence and those with distant metastasis. While older age is believed to be a poor prognostic marker for CM, rapid expansion of the aging population and its projected increase in the coming decades is expected to result in a large number of elderly melanoma patients seeking treatment in all stages of disease. This will not only bring with it unique management challenges in this population, but also an increased burden on communities to provide financial and social resources. Comprehensive efforts will need to be directed towards early diagnosis, as well as developing safe and effective treatment. Renewed interest in the cancer immune surveillance theory coupled with recognition of aging-associated weaknesses in the immune system has put the spotlight on immunsenescence as a important risk factor for the rising incidence of CM in the aging population. Comprehensive assessment of the aging immune system might shed light, not only on weaknesses of individual components of the adaptive immune system, but also on the critical imbalances resulting from these weaknesses on anti-melanoma immunity. Identifying these imbalances might help harness novel immune-based treatment of MM in selected elderly patients. This article describes our experience of treating elderly patients with MM and the issues unique to them, with particular emphasis on insights into the aging immune system.

摘要

皮肤黑素瘤(CM)是一种高度可治愈的黑素细胞皮肤癌,如果早期诊断。不幸的是,它侵入更深的真皮会增加其扩散到淋巴结和远处器官的风险。转移性黑素瘤(MM)扩散到其他器官是最危险的情况之一,对于大多数患者来说,目前可用的治疗方法几乎都是致命的。由于黑素瘤是一种免疫原性肿瘤,开发新的免疫策略将继续在设计针对高复发风险和远处转移患者的有效治疗方法方面发挥关键作用。虽然年龄较大被认为是 CM 的预后不良标志物,但人口老龄化的迅速扩张及其预计在未来几十年的增长预计将导致大量老年黑素瘤患者在疾病的所有阶段寻求治疗。这不仅会给该人群带来独特的管理挑战,还会给社区带来提供财务和社会资源的负担。需要全面努力实现早期诊断,并开发安全有效的治疗方法。癌症免疫监视理论的重新关注以及对免疫系统与年龄相关弱点的认识,使免疫衰老成为衰老人群中 CM 发病率上升的一个重要危险因素。对衰老免疫系统的全面评估不仅可以揭示适应性免疫系统各个组成部分的弱点,还可以揭示这些弱点对抗黑素瘤免疫产生的关键失衡。确定这些失衡可能有助于利用新型免疫治疗方法治疗选定的老年 MM 患者。本文描述了我们治疗老年 MM 患者的经验以及他们特有的问题,特别强调了对衰老免疫系统的深入了解。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验